|Bid||84.45 x 400|
|Ask||85.45 x 200|
|Day's Range||84.51 - 85.53|
|52 Week Range||64.18 - 86.72|
|PE Ratio (TTM)||40.98|
|Dividend & Yield||2.08 (2.46%)|
|1y Target Est||N/A|
Nasdaq futures fell Monday evening as Apple retreated following its Q2 earnings. Four stocks near buy points report earnings Tuesday morning, including GM and 3M.
Nektar neared a breakout on a deal with Lilly for a drug designed to fight autoimmune and inflammatory conditions.
Merck and Co Inc said on Thursday the U.S. Food and Drug Administration (FDA) tentatively approved its follow-on biologic version of French drugmaker Sanofi SA's blockbuster diabetes treatment, Lantus. Merck's copycat, if launched, would challenge Lantus as a cheaper alternative that could chip away at the drug's sales, which reached 5.71 billion euros ($6.6 billion) last year and represented over a sixth of Sanofi's total sales.